## Sheerazed Boulkroun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6605042/publications.pdf

Version: 2024-02-01

49 papers 3,343 citations

28 h-index 47 g-index

50 all docs 50 docs citations

50 times ranked

3154 citing authors

#	Article	IF	CITATIONS
1	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics, 2013, 45, 440-444.	9.4	460
2	Inhibition of MicroRNA-92a Prevents Endothelial Dysfunction and Atherosclerosis in Mice. Circulation Research, 2014, 114, 434-443.	2.0	317
3	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	1.3	248
4	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	1.3	246
5	WNT/ $\hat{l}^2$ -catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Human Molecular Genetics, 2014, 23, 889-905.	1.4	157
6	A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nature Genetics, 2018, 50, 355-361.	9.4	154
7	Characterization of Rat NDRG2 (N-Myc Downstream Regulated Gene 2), a Novel Early Mineralocorticoid-specific Induced Gene. Journal of Biological Chemistry, 2002, 277, 31506-31515.	1.6	131
8	Adrenal Cortex Remodeling and Functional Zona Glomerulosa Hyperplasia in Primary Aldosteronism. Hypertension, 2010, 56, 885-892.	1.3	128
9	CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism. EBioMedicine, 2016, 13, 225-236.	2.7	119
10	Genetic, Cellular, and Molecular Heterogeneity in Adrenals With Aldosterone-Producing Adenoma. Hypertension, 2020, 75, 1034-1044.	1.3	89
11	Aldosterone and tight junctions: modulation of claudin-4 phosphorylation in renal collecting duct cells. American Journal of Physiology - Cell Physiology, 2005, 289, C1513-C1521.	2.1	86
12	Aldosterone-Producing Adenoma Formation in the Adrenal Cortex Involves Expression of Stem/Progenitor Cell Markers. Endocrinology, 2011, 152, 4753-4763.	1.4	85
13	Mycolactone Suppresses T Cell Responsiveness by Altering Both Early Signaling and Posttranslational Events. Journal of Immunology, 2010, 184, 1436-1444.	0.4	76
14	Genetic Causes of Functional Adrenocortical Adenomas. Endocrine Reviews, 2017, 38, 516-537.	8.9	72
15	Deubiquitylation Regulates Activation and Proteolytic Cleavage of ENaC. Journal of the American Society of Nephrology: JASN, 2008, 19, 2170-2180.	3.0	65
16	Pathogenesis and treatment of primary aldosteronism. Nature Reviews Endocrinology, 2020, 16, 578-589.	4.3	65
17	Vasopressin-inducible ubiquitin-specific protease 10 increases ENaC cell surface expression by deubiquitylating and stabilizing sorting nexin 3. American Journal of Physiology - Renal Physiology, 2008, 295, F889-F900.	1.3	62
18	An update on novel mechanisms of primary aldosteronism. Journal of Endocrinology, 2015, 224, R63-R77.	1.2	56

#	Article	IF	Citations
19	Different Somatic Mutations in Multinodular Adrenals With Aldosterone-Producing Adenoma. Hypertension, 2015, 66, 1014-1022.	1.3	55
20	Concurrent primary aldosteronism and subclinical cortisol hypersecretion. Journal of Hypertension, 2011, 29, 1773-1777.	0.3	50
21	Somatic and inherited mutations in primary aldosteronism. Journal of Molecular Endocrinology, 2017, 59, R47-R63.	1.1	42
22	Long-term effects of vasopressin on the subcellular localization of ENaC in the renal collecting system. Kidney International, 2006, 69, 1024-1032.	2.6	41
23	KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Molecular and Cellular Endocrinology, 2013, 371, 221-227.	1.6	38
24	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. Nature Genetics, 2021, 53, 1360-1372.	9.4	37
25	(NDRG2) Stimulates Amiloride-sensitive Na+ Currents in Xenopus laevis Oocytes and Fisher Rat Thyroid Cells. Journal of Biological Chemistry, 2007, 282, 28264-28273.	1.6	33
26	Pathogenesis of hypertension in a mouse model for human CLCN2 related hyperaldosteronism. Nature Communications, 2019, 10, 4678.	5.8	33
27	Inherited forms of mineralocorticoid hypertension. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 633-645.	2.2	32
28	Mast Cell Hyperplasia Is Associated With Aldosterone Hypersecretion in a Subset of Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E550-E560.	1.8	32
29	Aldosterone-Producing Adenoma With a Somatic KCNJ5 Mutation Revealing APC-Dependent Familial Adenomatous Polyposis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3874-3878.	1.8	32
30	Calcyclin Is an Early Vasopressin-induced Gene in the Renal Collecting Duct. Journal of Biological Chemistry, 2002, 277, 25728-25734.	1.6	30
31	Expression of androgen receptor and androgen regulation of NDRG2 in the rat renal collecting duct. Pflugers Archiv European Journal of Physiology, 2005, 451, 388-394.	1.3	28
32	A network perspective on metabolic inconsistency. BMC Systems Biology, 2012, 6, 41.	3.0	26
33	Genetics in endocrinology: Genetics of mineralocorticoid excess: an update for clinicians. European Journal of Endocrinology, 2013, 169, R15-R25.	1.9	26
34	Vasopressin-stimulated CFTR Clâ^'currents are increased in the renal collecting duct cells of a mouse model of Liddle's syndrome. Journal of Physiology, 2005, 562, 271-284.	1.3	23
35	Functional histopathological markers of aldosterone producing adenoma and somatic KCNJ5 mutations. Molecular and Cellular Endocrinology, 2015, 408, 220-226.	1.6	23
36	Integrating Genetics and Genomics in Primary Aldosteronism. Hypertension, 2012, 60, 580-588.	1.3	22

#	Article	IF	Citations
37	Diastrophic Dysplasia Sulfate Transporter (SLC26A2) Is Expressed in the Adrenal Cortex and Regulates Aldosterone Secretion. Hypertension, 2014, 63, 1102-1109.	1.3	21
38	Molecular and Cellular Mechanisms of Aldosterone Producing Adenoma Development. Frontiers in Endocrinology, 2015, 6, 95.	1.5	20
39	Genetic and Genomic Mechanisms of Primary Aldosteronism. Trends in Molecular Medicine, 2020, 26, 819-832.	3.5	20
40	Bilateral Idiopathic Adrenal Hyperplasia: Genetics and Beyond. Hormone and Metabolic Research, 2015, 47, 947-952.	0.7	19
41	Old and new genes in primary aldosteronism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101375.	2.2	13
42	Retinoic acid receptor $\hat{l}_{\pm}$ as a novel contributor to adrenal cortex structure and function through interactions with Wnt and Vegfa signalling. Scientific Reports, 2019, 9, 14677.	1.6	10
43	Overview of aldosterone-related genetic syndromes and recent advances. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 147-154.	1.2	6
44	Molecular genetics of Conn adenomas in the era of exome analysis. Presse Medicale, 2018, 47, e151-e158.	0.8	5
45	Colocalization of Wnt/ $\hat{l}^2$ -Catenin and ACTH Signaling Pathways and Paracrine Regulation in Aldosterone-producing Adenoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 419-434.	1.8	5
46	Sgk: an old enzyme revisited. Journal of Clinical Investigation, 2002, 110, 1233-1234.	3.9	4
47	Germline and somatic genetic basis of primary aldosteronism. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 160-166.	0.6	0
48	SOMATIC MUTATIONS IN ADRENALS FROM PATIENTS WITH PRIMARY ALDOSTERONISM NOT CURED AFTER ADRENALECTOMY SUGGEST COMMON PATHOGENIC MECHANISMS BETWEEN UNILATERAL AND BILATERAL DISEASE. Journal of Hypertension, 2021, 39, e9.	0.3	0
49	From Genetic Abnormalities to Pathophysiological Mechanisms. , 2014, , 53-74.		O